CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The NANOp2lysis platform develops a technology for protecting enzymes and creating solid-state nanoparticles for targeted drug delivery. Its first application, O2L-001, is a treatment for intracerebral hematoma, enabling effective local injection and slow release of a new thrombolytic agent to improve outcomes after ac…
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles.
Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics). O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS).
It has been tailored to be loc…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Belgium, Herstal
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
